1. ACET's CEO, Chen Schor, will present at Jefferies Healthcare Conference. 2. The presentation is scheduled for June 4, 2025, at 4:20 p.m. ET. 3. The conference could enhance investor interest in ACET's therapies. 4. An archived video will be available for 30 days post-event. 5. ACET focuses on allogeneic gamma delta T cell therapies.
The participation in a major healthcare conference signifies investor confidence and visibility, which can positively impact share prices, akin to past similar events for biotech firms that led to price increases due to heightened investor interest and positive future outlooks.
The conference is a significant platform for ACET to communicate developments and engage with potential investors, which directly influences the company’s market perception and stock performance.
The upcoming event has immediate relevance, potentially affecting ACET's price soon after it occurs as investor sentiment can shift rapidly based on updates or discussions shared during such conferences.
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York.
Details of the event are as follows:
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.